1y return+75.3%S&P 500 +20.9%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2024: $171 against $127 in the S&P 500.2
Catalio Capital Management, LPS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| AVLNAvalyn Pharmaceuticals Inc | $55.2M | 10.4% | New |
| JNJJohnson & Johnson | $35.3M | 6.6% | New |
| GILDGilead Sciences Inc | $34.0M | 6.4% | +64.3% |
| BBIOBridgebio Pharma Inc | $33.9M | 6.4% | +5.3% |
| SNDXSyndax Pharmaceuticals Inc | $26.6M | 5.0% | +16.5% |
| DFTXDefinium Therapeutics Inc | $26.5M | 5.0% | −45.8% |
| BMYBristol-myers Squibb Co | $23.8M | 4.5% | −1.8% |
| PBLSParabilis Medicines Inc | $22.6M | 4.2% | New |
| NTRANatera Inc | $22.3M | 4.2% | +15.9% |
| INCYIncyte Corp | $21.7M | 4.1% | +5.2% |
| SEPNSepterna Inc | $18.0M | 3.4% | +82.1% |
| MLYSMineralys Therapeutics Inc | $17.5M | 3.3% | +47.8% |
| HTFLHeartflow Inc | $17.1M | 3.2% | +44.5% |
| CRVSCorvus Pharmaceuticals Inc | $16.1M | 3.0% | +21.2% |
| GPCRStructure Therapeutics Inc | $14.8M | 2.8% | +8.3% |
| PTGXProtagonist Therapeutics Inc | $13.1M | 2.5% | New |
| IRONDisc Medicine Inc | $11.7M | 2.2% | +29.6% |
| EWEdwards Lifesciences Corp | $11.3M | 2.1% | −13.7% |
| AXSMAxsome Therapeutics Inc. | $10.6M | 2.0% | New |
| RAREUltragenyx Pharmaceutical In | $10.6M | 2.0% | −62.8% |
| KLRAKailera Therapeutics Inc | $10.3M | 1.9% | New |
| KPTIKaryopharm Therapeutics Inc | $9.2M | 1.7% | +4.8% |
| ODTXOdyssey Therapeutics Inc | $8.6M | 1.6% | New |
| Ascendis Pharma A/sCUSIP K08588103 | $8.5M | 1.6% | New |
| KARDKardigan Inc | $7.5M | 1.4% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| DNTHDianthus Therapeutics Inc | December 31, 2024 | +347.2% | $3.2M |
| FTHFaeth Therapeutics Inc | June 30, 2025 | +191.4% | $368K |
| KPTIKaryopharm Therapeutics Inc | March 31, 2025 | +161.2% | $9.2M |
| DFTXDefinium Therapeutics Inc | March 31, 2026 | +148.9% | $26.5M |
| GPCRStructure Therapeutics Inc | December 31, 2024 | +97.9% | $14.8M |
| MANEVeradermics Inc | March 31, 2026 | +94.7% | $5.6M |
| SNDXSyndax Pharmaceuticals Inc | March 31, 2025 | +77.9% | $26.6M |
| NTRANatera Inc | June 30, 2025 | +60.7% | $22.3M |
| HYPRHyperfine Inc | December 31, 2024 | +53.4% | $1.8M |
| ELDNEledon Pharmaceuticals Inc | September 30, 2025 | +52.1% | $6.7M |
Sold off last quarter
- Ascendis Pharma A/sCUSIP 04351P101 was $29.5M
- Terns Pharmaceuticals IncCUSIP 880881107 was $21.6M
- Soleno Therapeutics IncCUSIP 834203309 was $19.3M
- BSXBoston Scientific Corp was $18.8M
- CYTKCytokinetics Inc was $14.2M
- ADPTAdaptive Biotechnologies Cor was $10.0M
- Kalvista Pharmaceuticals IncCUSIP 483497103 was $8.6M
- Uniqure NvCUSIP N90064101 was $8.0M
- ABVXAbivax Sa was $5.3M
- SUPNSupernus Pharmaceuticals was $3.2M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +22.7% | +14.8% |
| March 31, 2026 | −0.8% | −4.6% |
| December 31, 2025 | +25.9% | +2.4% |
| September 30, 2025 | +14.5% | +7.8% |
| June 30, 2025 | +2.7% | +10.5% |
| March 31, 2025 | −4.8% | −4.6% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Catalio Capital Management, LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1958125&type=13F-HR&dateb=&owner=include&count=40CIK 1958125
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1958125/000195812526000005/Filed August 14, 2026 · accession 0001958125-26-000005